AstraZeneca's (LON:AZN) stock up by 7.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s fundamentals to see if ...

AstraZeneca PLC closed 16.13% short of its 52-week high of £133.88, which the company reached on September 3rd.

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

AstraZeneca Plc‘s win over shareholders who challenged its $3 billion sale of biotech firm Viela Bio Inc. was affirmed ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing ...

AstraZeneca PLC AZN shares slid 1.34% to £114.52 Monday, on what proved to be an all-around rough trading session for the ...

Xponance Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.9% during the fourth quarter, ...

Bangalore: AstraZeneca Pharma India Limited has announced that the Company will be discontinuing the manufacturing and ...